SI-BONE develops minimally invasive implant systems and procedural solutions for spine and orthopedic applications, with particular expertise in treating sacroiliac joint dysfunction and degeneration in challenging bone density environments. The company's primary product, iFuse, is an implant system for sacroiliac joint fusion, and its technology platform extends to thoracolumbar fixation and pelvic trauma; several products have received FDA breakthrough device designations. SI-BONE generates revenue by selling implants and accompanying instrument trays to hospitals, medical groups, and ambulatory surgery centers in the United States and internationally, through a combination of direct sales staff and third-party agents, with revenue recognized upon procedure completion; the business model is driven by procedure volumes, product mix, pricing, and geographic distribution.